AI代理有望提升印度核医学抗癌研究与诊疗效率
The potential role of AI agents in transforming nuclear medicine research and cancer management in India
- 构建基于AI代理的医疗生态，优化核医学资源分配
- 应对印度癌症高死亡率（诊断后3/5死亡）的系统性挑战
- 适合关注医疗AI落地、公共卫生政策的研究者
印度面临严峻的癌症负担，诊断后近三成五患者死亡。尽管医疗基础设施受限，政府与机构正积极应对。但受地理广阔和人口密集影响，亟需软性技术方案补充。人工智能代理正在多个领域革新问题解决方式，尤其在医学中表现突出。本文探讨AI代理在印度核医学癌症研究、诊断与管理中的潜力，先简述AI代理能力，再提出可应对可持续性挑战的代理生态系统。
原文摘要 · Abstract (English)
India faces a significant cancer burden, with an incidence-to-mortality ratio indicating that nearly three out of five individuals diagnosed with cancer succumb to the disease. While the limitations of physical healthcare infrastructure are widely acknowledged as a primary challenge, concerted efforts by government and healthcare agencies are underway to mitigate these constraints. However, given the country's vast geography and high population density, it is imperative to explore alternative soft infrastructure solutions to complement existing frameworks. Artificial Intelligence agents are increasingly transforming problem-solving approaches across various domains, with their application in medicine proving particularly transformative. In this perspective, we examine the potential role of AI agents in advancing nuclear medicine for cancer research, diagnosis, and management in India. We begin with a brief overview of AI agents and their capabilities, followed by a proposed agent-based ecosystem that can address prevailing sustainability challenges in India nuclear medicine.
Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品；中文卡片由大模型生成，请以原文为准。